statistiche ricercatore

Continente	#
AS - Asia	784
NA - Nord America	497
EU - Europa	236
SA - Sud America	142
AF - Africa	28
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.689

Nazione	#
US - Stati Uniti d'America	463
CN - Cina	266
SG - Singapore	223
VN - Vietnam	121
BR - Brasile	104
IT - Italia	73
HK - Hong Kong	42
KR - Corea	40
GB - Regno Unito	32
RU - Federazione Russa	23
SE - Svezia	21
FR - Francia	20
IN - India	20
AR - Argentina	19
MX - Messico	18
NL - Olanda	17
DE - Germania	13
ZA - Sudafrica	13
PL - Polonia	12
TR - Turchia	12
CA - Canada	11
ID - Indonesia	10
JP - Giappone	9
EC - Ecuador	8
IQ - Iraq	8
BD - Bangladesh	6
CO - Colombia	6
FI - Finlandia	6
UA - Ucraina	5
UZ - Uzbekistan	4
AE - Emirati Arabi Uniti	3
DZ - Algeria	3
EG - Egitto	3
HR - Croazia	3
IL - Israele	3
MA - Marocco	3
PK - Pakistan	3
SA - Arabia Saudita	3
AT - Austria	2
AZ - Azerbaigian	2
CH - Svizzera	2
CL - Cile	2
GR - Grecia	2
MY - Malesia	2
PA - Panama	2
PE - Perù	2
RO - Romania	2
TN - Tunisia	2
AU - Australia	1
CI - Costa d'Avorio	1
CR - Costa Rica	1
ES - Italia	1
ET - Etiopia	1
JO - Giordania	1
KE - Kenya	1
KG - Kirghizistan	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LT - Lituania	1
NI - Nicaragua	1
PH - Filippine	1
PT - Portogallo	1
SN - Senegal	1
SR - Suriname	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.689

Nome	#
Patient derived organoids are an useful tool to investigate Hippo pathway involvement in lung cancer	158
The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling	150
Implementing an organoid platform to assess efficacy of PHD inhibitors as anti-cancer agents	136
Harnessing NK Cell Potential Against NSCLC	133
PHD2 (EGLN1) is a novel therapeutic target in KRAS-mutated lung carcinoma	133
Dissecting the role of lncRNAs in promoting Natural Killer cytotoxicity in Non-Small Cell Lung Cancer models	128
LncRNA TAZ-AS202 promotes lung cancer progression through the regulation of the E2F1 transcription factor	124
Unraveling NK Cell-Mediated Cytotoxicity in NSCLC	94
A Two-Step Protocol for Isolation and Maintenance of Lung Cancer Primary 3D Cultures	93
Exploring EGLN1/PHD2 role in KRAS mutated lung cancer: insights into mitochondrial modulation and therapeutic opportunities	92
Harnessing the hypoxia pathway to set a new therapeutic strategy for KRAS-mutated lung adenocarcinoma	90
null	83
Targeting EGLN1 to Overcome Drug Resistance in KRAS-Mutant Lung Adenocarcinoma: A Patient-Derived Organoid Study	80
Characterization of EGLN1 as a pro-oncogenic factor and pharmacological target in lung cancer	80
Leveraging NK Cell Potential Against NSCLC: insights from long-non coding RNAs	79
Exploring EGLN1 as a therapeutic target for KRAS mutated lung cancer	58
Totale	1.711

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2024/2025	365	0	19	17	24	62	46	44	22	43	15	39	34
2025/2026	1.346	74	92	196	245	215	70	181	62	141	70	0	0
Totale													1.711